Advertisement

Pharmacy World and Science

, Volume 27, Issue 6, pp 472–474 | Cite as

Secondary Prevention in Coronary Heart Disease: Goal Achievement and Drug Prescribing

  • Trude GiverhaugEmail author
  • Christine Bruland
  • Thor Trovik
Short Research Article

Abstract

Objective:

To provide an overview of the degree of treatment goal achievement and drug prescribing in patients with coronary heart disease (CHD) in clinical practice.

Method:

Patients undergoing planned or acute percutaneous coronary intervention (PCI) were included. Patients’ medical records and the hospital’s database on clinical chemistry analyses were studied retrospectively.

Main outcome measure

Goal achievement and drug prescription relative to published therapeutic guidelines.

Results

A total of 200 patients aged 66 ± 11 years were included. Blood pressure <140/90 mmHg was achieved in 36% of patients 3 months after PCI and total cholesterol <5 mmol/l was achieved in 29% at the time of PCI. Three months after PCI the patients were on 1.4 (range 0–4) drugs with antihypertensive effect (including diuretics). Seventy eight percent were on a statin, 92% were on low-dose aspirin, and 23% had a diuretic in their drug regimen. Five out of 16 patients with diabetes mellitus included in the study were prescribed an angiotensin converting enzyme-inhibitor (ACE-I).

Conclusion:

There is probably a potential for increased degree of goal achievement and for improved drug prescribing in patients with CHD undergoing PCI at our hospital.

Keywords

Coronary heart disease Norway Percutaneous coronary interventions Secondary prevention 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fihn, SD, Sankey, MPH, Daley, J, Gibbons, RJ 2001Guidelines for the management of patients with chronic stable angina: treatmentAnn Intern Med13561632PubMedGoogle Scholar
  2. 2.
    Elst, ME, Buurma, H, Bouvy, ML, Boer, A 2003Drug therapy for prevention of recurrent myocardial infarctionAnn Pharmacother37146577PubMedGoogle Scholar
  3. 3.
    Chobanian, AV, Bakris, GL, Black, HR, Cushman, WC, Green, LA, Izzo, JL,  et al. 2003The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressureJAMA289256072CrossRefPubMedGoogle Scholar
  4. 4.
    2003 European society of hypertension – European society of cardiology guidelines for the management of arterial hypertension. Guidelines committee. J Hypertens 2003; 21: 1011–53Google Scholar
  5. 5.
    Williams, B, Poulter, NR, Brown, MJ, Davis, M, McInnes, GT, Potter, JF,  et al. 2004British hypertension society guidelines for hypertension management 2004 (BHS-IV): summaryBMJ32863440PubMedGoogle Scholar
  6. 6.
    The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413–46Google Scholar
  7. 7.
    Wood, D, Backer, G, Færgeman, O, Graham, I, Mancia, G, Pyörälä, K,  et al. 1998Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary preventionEur Heart J191434503Google Scholar
  8. 8.
    Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes care 2003; 26: S5–20Google Scholar
  9. 9.
    MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22Google Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Trude Giverhaug
    • 1
    Email author
  • Christine Bruland
    • 1
  • Thor Trovik
    • 2
  1. 1.Institute of Pharmacy, Faculty of MedicineUniversity of TromsøTromsøNorway
  2. 2.Department of CardiologyUniversity Hospital of North-NorwayTromsøNorway

Personalised recommendations